The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …

Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …

Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …

Cancer immunotherapy can effectively inhibit cancer progression by activating the
autoimmune system, with low toxicity and high effectiveness. Some of cancer …

CD8+ T cells are critical mediators of cytotoxic effector function in infection, cancer and
autoimmunity. In cancer and chronic viral infection, CD8+ T cells undergo a progressive loss …